Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  16.00 5.26% 320.00 312.00 324.00 330.00 304.00 304.00 2,325,145 16:35:23
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -20.5 -26.2 - 250

Silence Therapeutics Share Discussion Threads

Showing 50401 to 50424 of 51475 messages
Chat Pages: Latest  2023  2022  2021  2020  2019  2018  2017  2016  2015  2014  2013  2012  Older
DateSubjectAuthorDiscuss
26/10/2018
15:21
(H/T FT AV) Amicus Therapeutics (Nasdaq FOLD) Possible name in the frame then.........
soundbuy
24/10/2018
17:38
Maybe some substance to the story. Alphaville is a bit more plausible than some of the so called tipsters
callumross
24/10/2018
17:17
My bad ., forget it
djnzloop
24/10/2018
17:16
Lots of trading activity appearing now
djnzloop
24/10/2018
14:31
"Shares in Silence Therapeutics PLC (LON:SLN) surged in early afternoon trading on rumours that the RNA interference specialist is being eyed up by potential buyers in the US. FTAlphaville said there seems to be “some gossip around right now about interest in Silence from the US”. It added that the biotech industry in the US is clustered around San Diego, name checking Cidara Therapeutics, although its market cap is smaller than Silence’s. FTAlphaville does caveat the story though, saying it is “just a rumour at this stage, so needs a RAW disclaimer”. Still, it got the market excited, with Silence immediately climbing 11.4% to 123.7p."
callumross
24/10/2018
13:03
Looking good. If this rise continues, at what point will it require comment from the company I wonder?
1gw
24/10/2018
11:52
Fingers crossed for substance then. Thanks from me too. Not long until they're scheduled to be in court for the patent litigation so now would be an obvious time for discussions with Alnylam to come to a head. I would have thought anyone other than Alny might want to wait until after the patent litigation was settled though - unless they were convinced that Silence was likely to win big.
1gw
24/10/2018
11:05
Thanks for this Tony. They would have to pay way, way more than the current price, that's for sure!
callumross
24/10/2018
10:55
bid target? https://ftalphaville.ft.com/marketslive/2018-10-24/ 11:34 am BE Okay, so here's a thing. 11:36 am Silence Therapeutics PLC (SLN:LSE): Last: 112.00, up 1 (+0.90%), Volume: 7.96k 11:36 am BE Always been one of the more interesting biotech stories in the smallcaps. 11:37 am BE RNAi therapies progressing towards approval, reasonable amount of cash, new management in place .... 11:38 am BE ........ legal stuff gradually resolving. 11:38 am BE Now, there seems to be some gossip around right now about interest in Silence from the US. 11:39 am BE The industry over there is clustered towards San Diego, with Nasdaq-listed Cidara among the bigger players. 11:40 am BE Just a rumour at this stage, though, so needs a RAW disclaimer. 11:41 am RAW is market chatter - information that has not been formally tested through traditional journalistic channels (PRs etc). The story might be complete rubbish, but if we believe there is some substance to it we will say so. Either way, Reader Beware.
tonysss13
12/10/2018
17:32
erratum in deed!
waterloo01
12/10/2018
16:23
Now that's an interesting mistake. I had a moment's panic when I read about the placing! But CAKE and SLN appear to have different brokers, so I'm not sure it can be taken as an indication that SLN are expecting to put out an RNS imminently, on raising funds, settling litigation or anything else. But how do you put out a CAKE RNS under the SLN name?
1gw
12/10/2018
07:16
Cant imagine why anybody would sell up at the moment, the news all appears very positive ,must make sense to hang around for a couple of months and let the story play out .
partner
11/10/2018
11:48
Yes, not the best day to announce what is undoubtedly good news. The news yesterday re seeking injunctive relief suggests that ALNY are either unwilling or reluctant to settle, though.
callumross
11/10/2018
11:30
I expect them to settle before the hearing. Could be any day, but the ex CEO purchase seems a good indicator it might be sooner rather than later. After all they have enough cash! Added a few this week and good to see the price hold firm in this correction.
waterloo01
11/10/2018
09:32
Very encouraging preliminary result, putting more pressure on ALNY in addition to the injunctive action against Patisiran announced yesterday. If their first commercial product cannot be sold in the EU pending clarification on the SLN action, now that really would pressurize them to settle.
callumross
05/10/2018
16:37
Interesting to compare the shares on loan position with the share price chart. According to Euroclear, SoL monthly average this year is as follows: 1.4m Jan (average shares on loan) 1.4m Feb 2.6m Mar 4.3m Apr 4.2m May 4.2m Jun 4.1m Jul 3.9m Aug 2.3m Sep So it looks like a significant increase in short positions in March and April (assuming the SoL correlates to short positions) may have helped to knock the shareprice off its 200p perch. hTtps://my.euroclear.com/apps/en/monthly-stock-loan-data.html#month=eq:9&year=eq:2018&limit=0&search=1&order=asc:abbreviation
1gw
05/10/2018
13:27
That's a big vote of confidence from Ali, I think. Great to see him putting his money in after leaving the CEO position. So I've bought another chunk there. It was right to follow him into ARWR, so I'm prepared to go with him on this as well.
1gw
04/10/2018
16:59
Will listen tonight. Makes you wonder why SLN are so ridiculously underperforming the sector - management changes, legal battles? In the next 3 months we have the Quark phase 3 results, the filing of the new trial drug and the legal action re Patisiran on 10th December so plenty newsflow.
callumross
04/10/2018
16:14
"Billion plus"? Did anyone else listen to the CEO's presentation at Cantor Fitzgerald? hTtps://www.silence-therapeutics.com/news-media/events/ Right at the end there's a bullish comment something like: "So that's why companies like Arrowhead, like Dicerna, are ramping up to the billion plus, and I think we'll not be far behind...simply because people see value, they see safety etc and they see a validated class in the pharmacopeia."
1gw
04/10/2018
15:16
Whoops. On the plus side, along with recent Alnylam updates the area seems to have some renewed interest.
waterloo01
04/10/2018
15:11
"J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion" "J&J will make a $75 million equity investment in Arrowhead at $23 per share, a premium of about 24 percent to the stock's Wednesday close. Arrowhead will also get $175 million upfront, the company said in a statement." hTtps://uk.finance.yahoo.com/news/j-j-arrowhead-gene-silencing-115253968.html
1gw
25/9/2018
12:01
Might get my next tranche at 110p by the look of things
volsung
24/9/2018
10:01
Silence Therapeutics will be presenting to investors at the upcoming Proactive One2One Forum on 4th October in Mayfair,London from 6pm. Details here: https://tinyurl.com/yb3j5c7z
aim_trader
11/9/2018
15:09
So much for that then
viku111
Chat Pages: Latest  2023  2022  2021  2020  2019  2018  2017  2016  2015  2014  2013  2012  Older
Your Recent History
LSE
SLN
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200119 00:28:44